H3K79 histone methyl transferase DOT1L inhibitor Compound 55 effect on breast cancer cells: dose response
Summary:
Analysis of MDA-MB-231 breast cancer cells treated with DOT1L (disruptor of telomeric silencing 1 like) inhibitor Compound 55 or DOT1L siRNA. DOT1L is a histone H3-lysine79 (H3K79) methyltransferase. Results provide insight into the role of DOT1L/H3K79 methylation in breast cancer.
Zhang L, Deng L, Chen F, Yao Y et al. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. Oncotarget 2014 Nov 15;5(21):10665-77. PMID: 25359765
